An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype.
Yun GuanYunzhu ShenYe XuChao LiJingwen WangWeilie GuPeng LianDan HuangSanjun CaiZhen ZhangZeng-Fu ShangPublished in: Therapeutic advances in gastroenterology (2019)
Our data demonstrated manageable toxicities and an encouraging CCR rate for UGT1A1 *1*1 genotype in an enhanced neoadjuvant therapy. A phase III trial is ongoing to evaluate the value of irinotecan in neoadjuvant therapy (CinClare) [ClinicalTrials.gov identifier: NCT02605265].
Keyphrases
- rectal cancer
- locally advanced
- phase iii
- open label
- clinical trial
- phase ii study
- squamous cell carcinoma
- radiation therapy
- phase ii
- lymph node
- early stage
- double blind
- placebo controlled
- study protocol
- regulatory t cells
- randomized controlled trial
- immune response
- data analysis
- replacement therapy
- machine learning
- deep learning